Recipharm bolsters development business with new appointments in the US and Europe

Recipharm, the contract development and manufacturing organisation (CDMO), has appointed Anders Högdin and Aaron Small to lead the growth of its pharmaceutical development services business in the US and Europe.

Since forming in Sweden in 1995, Recipharm has experienced strong year-on-year growth and is now operating from 20+ sites across 10 countries. In addition to its manufacturing services offering, Recipharm delivers pharmaceutical development services from the early discovery phase to supply of clinical trial materials from facilities in Sweden, Italy, France, Israel and the US. Parallel to these new appointments, Recipharm has strengthened the respective sales team in order to create focus on customer management and new business opportunities.

Based in Stockholm, Sweden, Anders Högdin will head the business development and sales team within development services in Europe. Anders has a MSc in chemistry and a PhD in organic chemistry from Uppsala University. Before joining Recipharm in 2015, he was employed at Syntagon, APL and OnTarget Chemistry in various roles.

Focused on driving the growth of the Recipharm’s North American business, Aaron Small will work in close contact with the Recipharm facility in Research Triangle Park, North Carolina. Aaron has a BSc in marketing and a Master of Business Administration and has been part of Recipharm’s business management function since 2012.

Commenting on the appointments, Carl-Johan Spak, Executive Vice President, Global Technologies said: “Over the past year, Recipharm’s development business has continued to expand, with the integration of new facilities, technologies and capabilities. The new North American sales organisation will be extremely important for Recipharm as it will enable the company to attract US customers to its extensive network of development and manufacturing facilities outside of the US”.

“We are very pleased to have such skilled, ambitious and enthusiastic professionals like Anders and Aaron to lead these two sales teams. Their contributions will be extremely valuable in the development of our business in offering new and existing customers access to our world class contract development and manufacturing services.”

Contact information
Carl-Johan Spak, Executive Vice President Global Technologies, carl-johan.spak@recipharm.com , + 46 8 602 53 13

For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com ,+ 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) (in the pharmaceutical industry employing around 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and its services, please visit www.recipharm.com

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden,  Telephone 46 8 602 52 00,  Fax  46 8 81 87 03

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

Over the past year, Recipharm’s development business has continued to expand, with the integration of new facilities, technologies and capabilities. The new North American sales organisation will be extremely important for Recipharm as it will enable the company to attract US customers to its extensive network of development and manufacturing facilities outside of the US. We are very pleased to have such skilled, ambitious and enthusiastic professionals like Anders and Aaron to lead these two sales teams. Their contributions will be extremely valuable in the development of our business in offering new and existing customers access to our world class contract development and manufacturing services.
Carl-Johan Spak, Executive Vice President, Global Technologies